The House of Representatives has passed HR 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act), as well as 2 other bills dealing with drug prices: HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and HR 938, the Bringing Low-cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act of 2019.
The House of Representatives has passed HR 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act), as well as 2 other bills dealing with drug prices: HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and HR 938, the Bringing Low-cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act of 2019.
Whether or not the bills, which generally have bipartisan support, progress through the Senate and onto the president’s desk remains to be seen. The bills were packaged into the larger HR 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act, which includes other bills targeting the Trump administration’s actions towards the Affordable Care Act.
The Washington Post reported recently that the move is aimed at undermining any Republican messaging on healthcare, as it restores funding for Affordable Care Act marketing and outreach as well as rescinds the expansion of short-term, limited duration health plans.
The CREATES Act has enjoyed broad bipartisan support since it was first introduced. It would allow a biosimilar or generic developer to bring a civil action against an innovator drug company if the latter refuses to make available enough samples of a product for testing. A parallel piece of legislation is also before the Senate.
CREATES was the target of heavy opposition from the Pharmaceutical Research and Manufacturers of America, which says that the proposed legislation would expose brand-name drug makers to significant risk and hinder innovation. But it has been praised by the Association of Accessible Medicines (AAM), which represents generic and biosimilar drug makers.
The BLOCKING Act discourages generic drug makers from delaying the start of their 180-day exclusivity period, allowing the FDA to approve a second generic application before the start of the first applicant’s commercial marketing.
The Protecting Consumer Access to Generic Drugs Act makes future pay-for-delay settlements between brand and generic drug manufacturers illegal. One report noted that in negotiations, Democrats agreed to a Republican request to strip out a portion of the bill that would have retroactively affected enforcement to 2013.
In a statement, AAM praised Congress for passing the CREATES Act, but said that, “Unfortunately, by packaging the CREATES Act with HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and HR 938, the BLOCKING Act of 2019, Congress has taken one step forward and two steps back. These bills, while well intentioned, will impede generic and biosimilar drug manufacturers from bringing new, safe, and more affordable medicines to market. HR 1499 and HR 938 will raise the price of medicine.”
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.